ToolGen Inc. announced data demonstrating that blocking a molecular pathway that down-regulates T-cell activity with the company's CRISPR/Cas9 gene editing platform results in increased T-cell receptor signaling, in vitro, and in improved anti-tumor activity when tested against in a mouse glioblastoma tumor model. The study is being presented in a poster presentation at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting held May 16 to May 9, 2018, in Chicago.